Anatara Lifesciences Ltd · ASX:ANR
Anatara Lifesciences — Shareholder Meeting (November 2019)
18 slides from Anatara Lifesciences's shareholder meeting presentation, Nov 11, 2019
Slide 1: Annual General Meeting
Annual General Meeting 11 November 2019 For personal use only Advancing gastrointestinal health
Slide 2: Disclaimer
Disclaimer For personal use only The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN
Slide 3: Key Investor Message
Key Investor Message For personal use only More than ever, the world is looking for safe and effective solutions to gut health. The Anatara team is focussed on delivering evidence-based, commercially attractive solutions for gastrointestinal diseases in animals and humans.
Slide 4: Corporate Fast Facts
Corporate Fast Facts Board of Directors: Sue MacLeman For personal use only Share Price ASX ticker code Dr Jane Ryan Dr Tracie Ramsdale $0.22* ANR Dr David Brookes Management: Steve Lydeamore, CEO Dr Tracey Brown, CDO Ordinary Shares Market Capitalisation Dr Michael West, COO 49,562,693 $10.9 millio
Slide 5: Investment highlights: multiple shots on goal
Investment highlights: multiple shots on goal For personal use only Human health asset, GaRP: • Aimed at restoring and maintaining gut health with excellent (pre-clinical in vitro and in vivo animal studies) data • Human clinical study protocol anticipated late 2019 with a view to commencement in 2Q
Slide 6: Detach Next Steps
Detach® Next Steps For personal use only Detach® increases survivability and provides health benefits to pre-weaning piglets • Growing demand for non-antibiotic solutions for livestock health • APVMA approved • Secure international animal health partner(s) by end FY 2020 – discussions underway with
Slide 7: Burgeoning microbiome market: our first targets
Burgeoning microbiome market: our first targets For personal use only Source: http://big.assets.huffingtonpost.com/2015_GutBacteriaA.png
Slide 8: Profound impact on patients
Profound impact on patients For personal use only “I feel teary eyed when I have to tell you this. It really does stop you from a lot of things in life like going away – you’re always afraid that something’s going to happen. Or if I do go away – where is the closest hospital? And am I going to ruin
Slide 9: IBS and IBD in a minute
IBS and IBD in a minute 11% >5m For personal use only With accelerating incidence, IBS affects around 11% of IBD has an estimated the global population2 >5million sufferers worldwide3 • Patients experience symptoms such as • Up to 50% of IBS/IBD patients turn to pain, bloating and diarrhoea dietary
Slide 10: Major Consumer Health Opportunity
Major Consumer Health Opportunity For personal use only US $5b OTC** digestive remedies 9 US $5.7b Global probiotic US $3b GI* supplement sales 10 supplement sales11 Other GI supplements OTC digestive supplements Probiotic supplements Iberogast® (Bayer) sales (Germany): Buscopan® (Sanofi) sales (Glo
Slide 11: How are the primary underlying factors of IBS and IBD addressed?
3 primary underlying factors of IBS and IBD How are these addressed? For personal use only Dietary modification Probiotics – limited evidence for clinical efficacy Anti-inflammatory drugs – severe side effect profile GaRP No direct treatments with long term results *Gastrointestinal ReProgramming (G
Slide 12: Changing the game for IBS and IBD
Changing the game for IBS and IBD Gastrointestinal ReProgramming (GaRP) For personal use only dietary supplement • Grounded in scientific evidence • Regenerative, multi-component dietary supplement • Triple-targeted therapeutic approach • anti-adhesion; • anti-inflammatory; • mucosal regeneration •
Slide 13: Before
Before For personal use only • Microbial imbalance • Excess pro-inflammatory bacteria • Compromised gut integrity • Excess inflammation proteins • Gut permeability • Damaged mucosal layer
Slide 14: During
During For personal use only • Rebalance microbiome • Inhibition of attachment and invasion of pro- inflammatory bacteria • Restore gut integrity • Inhibition of pro- inflammatory proteins • Reduction in colon inflammation • Regenerate mucosal layer • Increased mucin gene expression to promote mucos
Slide 15: After
After For personal use only • Rebalanced microbiome • Restored gut integrity • Regenerated mucosal layer
Slide 16: GaRP has been shown to…
GaRP has been shown to….. For personal use only • Address the dysbiosis of the microbiome • Inhibiting the attachment and invasion of pro-inflammatory bacteria by >95% • Reduce gut inflammation • Reducing the production of pro-inflammatory proteins by >85% • Reducing colon inflammation and disrupted
Slide 17: Anticipated Milestones
Anticipated Milestones 2018 H1 2018 H2 2019 H1 2019 H2 2020 H1 2020 H2 For personal use only GaRP commercial feasibility Patent Application filed In vitro GaRP proof of concept - anti-inflammation - anti-attachment In vitro GaRP proof of concept - mucosal healing GaRP animal study (IBD) -
Slide 18: Contact Anatara Lifesciences Ltd
For personal use only Contact Anatara Lifesciences Ltd Steven Lydeamore, CEO +61 438 027 172 slydeamore@anatara.com www.anataralifesciences.com @AnataraANR anatara-lifesciences-ltd
Anatara Lifesciences — Shareholder Meeting (November 2019) on 6ix